Kymera Therapeutics announced positive clinical results from the BroADen Phase 1b atopic dermatitis (AD) clinical trial of KT-621, its first-in-class, oral STAT6 degrader medicine.
KT-621 achieved deep STAT6 degradation across different dose groups tested, showing strong translation from healthy volunteers to AD patients.
The trial demonstrated robust clinical activity and improvements in disease-related biomarkers, with no serious adverse events reported.
Deep STAT6 Degradation
KT-621 achieved median reductions of 94% and 98% in skin and blood, respectively, demonstrating effective degradation of STAT6.
Reductions in Disease-Relevant Biomarkers
Strong reductions were observed in Type 2 biomarkers in blood, core Type 2 inflammation, and AD disease-related gene sets in skin lesions.
Clinical Activity and Patient Benefits
The trial showed significant reductions in EASI and peak pruritus NRS, improvement in asthma control, and quality-of-life benefits for patients with comorbid conditions.
- The results from the trial highlighted the potential of KT-621 to provide a once-a-day oral treatment for Type 2 inflammatory diseases.
- KT-621 demonstrated consistency in all measured endpoints, showing promising impact on clinical endpoints and disease-related biomarkers.
- These results signify a significant advancement in the treatment of atopic dermatitis and other Type 2 allergic diseases.
The positive outcomes of the BroADen Phase 1b trial of KT-621 showcase its potential as an innovative and well-tolerated treatment option for patients with moderate to severe AD. Kymera Therapeutics is on track with further trials to explore the broader application of this novel medicine in treating immunological diseases.